NCT03688802View on ClinicalTrials.gov

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Dry Eye Disease
Interventions
DRUG

OC-01 (varenicline) nasal spray

OC-01 (varenicline) nasal spray

DRUG

Placebo (vehicle control) nasal spray

Placebo

Trial Locations (1)

02111

Tufts, Boston

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation | Biotech Hunter | Biotech Hunter